WALTHAM, Mass.--(BUSINESS WIRE)--OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Harald Stock, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 25th Annual Credit Suisse Healthcare Conference on Monday, November 7, 2016 at 8:30 a.m. MT (10:30 a.m. ET) at The Phoenician in Scottsdale, Arizona.
A live audio webcast of the presentation can be accessed by visiting the investor section of the company’s website at www.ovascience.com. A replay of the webcast will be achieved on the OvaScience website for 30 days following the presentation.
About OvaScience
OvaScience℠ (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC℠) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT℠ treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience is developing the OvaPrime℠ treatment, which could increase a woman’s egg reserve, and the OvaTure℠ treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S. For more information, visit www.ovascience.com and www.augmenttreatment.com with us on Twitter and Facebook.
